发布求助
文献互助 智能选刊 最新文献

Annals of Pancreatic Cancer最新文献

筛选
英文 中文
Malnutrition, frailty, and sarcopenia in pancreatic cancer patients: assessments and interventions for the pancreatic surgeon. 胰腺癌患者的营养不良、虚弱和肌肉减少症:胰腺外科医生的评估和干预措施。
Annals of Pancreatic Cancer Pub Date : 2019-03-01 Epub Date: 2019-03-11 DOI: 10.21037/apc.2019.02.01
Noah S Rozich, Caitlin E Jones, Katherine T Morris
{"title":"Malnutrition, frailty, and sarcopenia in pancreatic cancer patients: assessments and interventions for the pancreatic surgeon.","authors":"Noah S Rozich,&nbsp;Caitlin E Jones,&nbsp;Katherine T Morris","doi":"10.21037/apc.2019.02.01","DOIUrl":"https://doi.org/10.21037/apc.2019.02.01","url":null,"abstract":"<p><p>The objective of this article is to review the available literature examining the impact of malnutrition, frailty, and sarcopenia on surgical morbidity among pancreatic cancer patients. We examine definitions used to diagnose and quantify these conditions and review the differences between them with regards to preoperative assessment and postoperative outcomes. The most relevant scoring systems are summarized. Lastly, we summarize current knowledge regarding effectiveness of specific interventions aimed at malnutrition, frailty, and sarcopenia for patients undergoing pancreatic cancer surgery.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"2 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2019.02.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25345116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Eugene J. Koay: translating promising new radiation technologies to patients with gastrointestinal cancers Eugene J. Koay:将有前途的新放射技术转化为胃肠道癌症患者
Annals of Pancreatic Cancer Pub Date : 2019-01-01 DOI: 10.21037/apc.2018.12.01
Brad Li
{"title":"Eugene J. Koay: translating promising new radiation technologies to patients with gastrointestinal cancers","authors":"Brad Li","doi":"10.21037/apc.2018.12.01","DOIUrl":"https://doi.org/10.21037/apc.2018.12.01","url":null,"abstract":"Gastrointestinal (GI) cancer refers to the group of cancers that affect the digestive system. This includes cancers of the oesophagus, stomach, liver, pancreas, gallbladder and biliary tract, small intestine, colon, rectum and anus. GI cancers are regarded as a highly virulent neoplasm with both high morbidity and mortality. Collectively, they are a major cause of morbidity and mortality worldwide (1). Over the past half century, modern radiation therapy has been established and slowly evolved to treat different kinds of GI cancers. However, challenges remain in giving accurate and safe radiation delivery.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79022932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pitfalls of minimally invasive pancreatoduodenectomy. 微创胰十二指肠切除术的陷阱。
Annals of Pancreatic Cancer Pub Date : 2019-01-01 Epub Date: 2019-01-16 DOI: 10.21037/apc.2018.12.02
Patrick W Underwood, Michael H Gerber, Steven J Hughes
{"title":"Pitfalls of minimally invasive pancreatoduodenectomy.","authors":"Patrick W Underwood,&nbsp;Michael H Gerber,&nbsp;Steven J Hughes","doi":"10.21037/apc.2018.12.02","DOIUrl":"https://doi.org/10.21037/apc.2018.12.02","url":null,"abstract":"<p><p>Minimally invasive approaches to abdominal surgical procedures have provided superior outcomes when compared to the open approach and thus have become the standard of care. However, minimally invasive pancreatoduodenectomy (MIPD) presents unique difficulties for both laparoscopic and robotic platforms and remains controversial. Ongoing concerns continue about the minimally invasive approach creating meaningful benefit when system-wide data may suggest MIPD results in increased morbidity and mortality during the learning curve. This treatise explores the current state of MIPD, reviewing the volume and quality of data that supports benefit while contrasting the benefits to the unique challenges associated with MIPD that may lead to unacceptable rates of complications and death. We conclude that in a handful of centers, MIPD confers an iterative but not transformative benefit. Significant barriers to the wide-spread acceptance of MIPD are apparent and persist, including: lack of high level data confirming clinical benefit, well defined patient selection criteria, formal education programs that address challenges of the learning curve, and ultimately value.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"2 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.12.02","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37641522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Immune defects in pancreatic cancer. 胰腺癌的免疫缺陷。
Annals of Pancreatic Cancer Pub Date : 2018-12-01 Epub Date: 2018-12-06 DOI: 10.21037/apc.2018.11.01
Lei Zheng
{"title":"Immune defects in pancreatic cancer.","authors":"Lei Zheng","doi":"10.21037/apc.2018.11.01","DOIUrl":"https://doi.org/10.21037/apc.2018.11.01","url":null,"abstract":"Pancreatic cancer is resistant to the immunotherapy. This resistance is caused by any of the four immune \"defects\" that occur in pancreatic cancer, including lack of \"high quality\" T cells, stromal barriers to T cells getting access to tumor cells, immunosuppressive cells such as M2 macrophages, myeloid derivative suppressor cells, and T regulatory cells, in the tumor microenvironment of pancreatic cancer. One or more defects may occur in an individual pancreatic cancer. To overcome the resistance to the immunotherapy such as immune checkpoint inhibitors, a rational combination of agents that target multiple immune defects is highly demanded.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"1 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.11.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36838418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Pancreatic cystic neoplasms: usually incidental, rarely incident 胰腺囊性肿瘤:通常是偶发的，很少是偶然发生的
Annals of Pancreatic Cancer Pub Date : 2018-10-01 DOI: 10.21037/APC.2018.09.04
E. Duell
{"title":"Pancreatic cystic neoplasms: usually incidental, rarely incident","authors":"E. Duell","doi":"10.21037/APC.2018.09.04","DOIUrl":"https://doi.org/10.21037/APC.2018.09.04","url":null,"abstract":"There are over 20 different types of cystic lesions of the pancreas, most of which are benign (1). The four most common pancreatic cysts with neoplastic potential are serous cystadenoma (SCA), solid pseudopapillary neoplasm (SPN), mucinous cystic neoplasm (MCN), and intraductal papillary mucinous neoplasm (IPMN).","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88507346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case analysis of pancreatic cancer treated with FOLFIRINOX in China 国内FOLFIRINOX治疗胰腺癌病例分析
Annals of Pancreatic Cancer Pub Date : 2018-10-01 DOI: 10.21037/APC.2018.09.01
S. Si, T. Hieken, A. Degnim, Zhiying Yang, H. Tan, Yongliang Sun, Liguo Liu, Wenying Zhou, Jia Huang
{"title":"Case analysis of pancreatic cancer treated with FOLFIRINOX in China","authors":"S. Si, T. Hieken, A. Degnim, Zhiying Yang, H. Tan, Yongliang Sun, Liguo Liu, Wenying Zhou, Jia Huang","doi":"10.21037/APC.2018.09.01","DOIUrl":"https://doi.org/10.21037/APC.2018.09.01","url":null,"abstract":"Background: The FOLFIRINOX regimen recently became the new standard of care for patients with advanced pancreatic cancer. However, FOLFIRINOX hasn’t been widely used in China as the hesitance of oncologists to use FOLFIRINOX due to the toxicity of the regimen and the presumption that Chinese patients could not tolerate FOLFIRINOX. \u0000 Methods: We retrospectively analyzed the clinical data of ten patients with pancreatic cancer who received the FOLFIRINOX regimen from July 2016 to July 2018. The two woman and eight men enrolled were aged 29 to 76 years. Three, three, and four patients were diagnosed with borderline resectable pancreatic cancer (BRPC), liver-metastatic pancreatic cancer (LMPC), and recurrent pancreatic cancer (RPC), respectively. Seven and three patients received a full or 80% initial dose, according to their Eastern Cooperative Oncology Group performance status. \u0000 Results: One of the seven patients was administered an 80% dose after the second cycle because of febrile neutropenia (grade >3). The most common adverse event was neutropenia (grade 2). Four patients with BRPC or LMPC successfully underwent surgical resection. Two patients with LMPC achieved partial remission (PR). The levels of the serum carbohydrate antigen 19-9 of three patients with RPC significantly decreased (>60%). \u0000 Conclusions: The FOLFIRINOX regimen is effective and is tolerated by certain Chinese patients with advanced pancreatic cancer. The dose of the FOLFIRINOX regimen should be individually adjusted to reduce toxicity.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"2181 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91387022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells. 对糖的应激:血清素在胰腺癌细胞糖酵解中的新作用。
Annals of Pancreatic Cancer Pub Date : 2018-10-01 Epub Date: 2018-10-10 DOI: 10.21037/apc.2018.09.03
Gregory B Lesinski
{"title":"Stressing for sugar: a new role of serotonin for glycolysis in pancreatic cancer cells.","authors":"Gregory B Lesinski","doi":"10.21037/apc.2018.09.03","DOIUrl":"https://doi.org/10.21037/apc.2018.09.03","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"1 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.09.03","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38047564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Depletion of tumor associated macrophages by anti-BAG3 treatment complements PD-1 blockade in pancreatic cancer 在胰腺癌中，抗bag3治疗对肿瘤相关巨噬细胞的消耗是对PD-1阻断的补充
Annals of Pancreatic Cancer Pub Date : 2018-10-01 DOI: 10.21037/APC.2018.10.01
Yi Sun, R. Torphy, Yuwen Zhu
{"title":"Depletion of tumor associated macrophages by anti-BAG3 treatment complements PD-1 blockade in pancreatic cancer","authors":"Yi Sun, R. Torphy, Yuwen Zhu","doi":"10.21037/APC.2018.10.01","DOIUrl":"https://doi.org/10.21037/APC.2018.10.01","url":null,"abstract":"New literature published in Gut has shown that combined treatment of anti-BAG3 mAb and anti-PD-1 mAb in pancreatic cancer can eliminate tumor-associated macrophages (TAMs), increase tumor infiltrating CD8+ T cells and result in tumor growth suppression (1). These findings highlight the potential of BAG3 (Bcl-2-associated athanogene 3) as a therapeutic target in conjunction with immune checkpoint blockade in the treatment of pancreatic cancer.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81726680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uncovering the role of immunosuppressive dendritic cells in pancreatic cancer 揭示免疫抑制树突状细胞在胰腺癌中的作用
Annals of Pancreatic Cancer Pub Date : 2018-09-01 DOI: 10.21037/APC.2018.09.02
D. Thomas, A. Murphy
{"title":"Uncovering the role of immunosuppressive dendritic cells in pancreatic cancer","authors":"D. Thomas, A. Murphy","doi":"10.21037/APC.2018.09.02","DOIUrl":"https://doi.org/10.21037/APC.2018.09.02","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a debilitating disease that continues to have rising incidence and mortality rates. In 2018, it is estimated that nearly 56,000 individuals will be newly diagnosed with pancreatic cancer (1). Surgical resection remains the only possible curative measure as pancreatic cancer is notoriously resistant to systemic chemotherapy, has high rates of recurrence, and is associated with a 5-year survival rate of 8.5 (1).","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73285417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. 可切除胰腺癌的辅助治疗策略。
Annals of Pancreatic Cancer Pub Date : 2018-08-01 Epub Date: 2018-08-06 DOI: 10.21037/apc.2018.07.05
Nikhil Yegya-Raman, Mihir M Shah, Miral S Grandhi, Elizabeth Poplin, David A August, Timothy J Kennedy, Usha Malhotra, Kristen R Spencer, Darren R Carpizo, Salma K Jabbour
{"title":"Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma.","authors":"Nikhil Yegya-Raman,&nbsp;Mihir M Shah,&nbsp;Miral S Grandhi,&nbsp;Elizabeth Poplin,&nbsp;David A August,&nbsp;Timothy J Kennedy,&nbsp;Usha Malhotra,&nbsp;Kristen R Spencer,&nbsp;Darren R Carpizo,&nbsp;Salma K Jabbour","doi":"10.21037/apc.2018.07.05","DOIUrl":"https://doi.org/10.21037/apc.2018.07.05","url":null,"abstract":"<p><p>Of all patients diagnosed with pancreatic adenocarcinoma, only 15-20% present with resectable disease. Despite curative-intent resection, the prognosis remains poor with the majority of patients recurring, prompting the need for adjuvant therapy. Historical data support the use of adjuvant 5-fluorouracil (5-FU) or gemcitabine, but recent data suggest either gemcitabine plus capecitabine or modified FOLFIRINOX can improve overall survival when compared to gemcitabine alone. The use of adjuvant chemoradiation therapy remains controversial, primarily due to limitations in study design and mixed results of historical trials. The ongoing Radiation Therapy Oncology Group (RTOG)-0848 trial hopes to further define the role of adjuvant chemoradiation therapy. Intraoperative radiation therapy (IORT) and adjuvant immunotherapy represent additional possibilities to improve outcomes, but evidence supporting their use is limited. This article reviews adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma, including chemotherapy, chemoradiation therapy, IORT and immunotherapy.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":"1 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/apc.2018.07.05","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36903219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信